GoAI
Get started
Ping An Healthcare and Technology Company Limited logo

Ping An Healthcare and Technology Company Limited

1833.HK

HKSEHealthcareMedical - Healthcare Information Services

Open in GoAI

Latest quote

HK$6.60

−HK$0.135 · -2.00%

Aug 24, 3:07 PM HKT

1833.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Ping An Healthcare and Technology Company Limited (PAHT), through its subsidiaries, operates a comprehensive online platform that delivers healthcare services across the People's Republic of China. Its core offerings encompass virtual medical consultations, facilitated hospital referrals and appointment scheduling, inpatient care coordination, and expert second opinions. PAHT also provides standardized consumer healthcare packages, integrating services from a network of medical institutions. Beyond services, the company offers a broad array of products, including pharmaceuticals, health supplements, medical devices, wellness items such as fitness equipment and personal care products, and other miscellaneous goods. Furthermore, PAHT engages users with health management and wellness interaction services, featuring various programs, interactive tools, activities, and personalized content. Its additional operations include medicine marketing, technology services, application development and maintenance, direct hospital and clinic services, and the management of an insurance agency. Established in 2014, Ping An Healthcare and Technology Company Limited maintains its headquarters in Shanghai, China.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
CN
CEO
Mingke He
Listed since
May 4, 2018
Employees
1,668

Market position

Day range

Current HK$6.60

52-week range

Current HK$6.60

Open
HK$6.735
Previous close
HK$6.735
Volume
7.09M
0.61× average
Average volume
11.56M
Average daily volume
Market cap
14.04B HKD
Beta
1.14
Market reference 1
50-day average
HK$7.5587
-12.68% below average
200-day average
HK$11.619
-43.20% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
23.73B CNY
EV / EBITDA
99.44×
Earnings yield
1.45%
Free cash flow yield
1.50%

Profitability & efficiency

Return on equity
3.83%
Return on assets
2.87%
Return on invested capital
0.96%

Financial health

Current ratio
2.7×
Altman Z-score
3.2
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends38%16%-6%-28%Gross margin, FY2021: 23.27%Gross margin, FY2022: 26.93%Gross margin, FY2023: 32.28%Gross margin, FY2024: 31.68%Gross margin, FY2025: 32.41%Operating margin, FY2021: -22.41%Operating margin, FY2022: -11.71%Operating margin, FY2023: -12.31%Operating margin, FY2024: -1.85%Operating margin, FY2025: 1.78%Net margin, FY2021: -20.97%Net margin, FY2022: -10.25%Net margin, FY2023: -6.90%Net margin, FY2024: 1.69%Net margin, FY2025: 6.94%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 23.27%. Gross margin FY2022 26.93%. Gross margin FY2023 32.28%. Gross margin FY2024 31.68%. Gross margin FY2025 32.41%. Operating margin FY2021 -22.41%. Operating margin FY2022 -11.71%. Operating margin FY2023 -12.31%. Operating margin FY2024 -1.85%. Operating margin FY2025 1.78%. Net margin FY2021 -20.97%. Net margin FY2022 -10.25%. Net margin FY2023 -6.90%. Net margin FY2024 1.69%. Net margin FY2025 6.94%.

Income trends

Revenue

5.47B CNY+13.73%

Operating income

97.6M CNY+186.67M CNY

Net income

379.51M CNY+366.07%
Income trends across reported periods8.23B CNY4.64B CNY1.05B CNY−2.54B CNYRevenue, FY2021: 7.33B CNYRevenue, FY2022: 6.21B CNYRevenue, FY2023: 4.67B CNYRevenue, FY2024: 4.81B CNYRevenue, FY2025: 5.47B CNYOperating income, FY2021: −1.64B CNYOperating income, FY2022: −726.34M CNYOperating income, FY2023: −575.26M CNYOperating income, FY2024: −89.06M CNYOperating income, FY2025: 97.6M CNYNet income, FY2021: −1.54B CNYNet income, FY2022: −636.06M CNYNet income, FY2023: −322.59M CNYNet income, FY2024: 81.43M CNYNet income, FY2025: 379.51M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 7.33B CNY. Revenue FY2022 6.21B CNY. Revenue FY2023 4.67B CNY. Revenue FY2024 4.81B CNY. Revenue FY2025 5.47B CNY. Operating income FY2021 −1.64B CNY. Operating income FY2022 −726.34M CNY. Operating income FY2023 −575.26M CNY. Operating income FY2024 −89.06M CNY. Operating income FY2025 97.6M CNY. Net income FY2021 −1.54B CNY. Net income FY2022 −636.06M CNY. Net income FY2023 −322.59M CNY. Net income FY2024 81.43M CNY. Net income FY2025 379.51M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue5.47B CNY4.81B CNY4.67B CNY6.21B CNY7.33B CNY
Cost of goods sold3.7B CNY3.28B CNY3.17B CNY4.48B CNY5.63B CNY
Gross profit1.77B CNY1.52B CNY1.51B CNY1.67B CNY1.71B CNY
Selling, general, and administrative1.67B CNY1.69B CNY2.32B CNY2.87B CNY3.6B CNY
Operating expenses1.67B CNY1.61B CNY2.08B CNY2.4B CNY3.35B CNY
Interest income109.16M CNY185.96M CNY262.08M CNY269.05M CNY310.46M CNY
Interest expense2.68M CNY3.4M CNY6.89M CNY11.11M CNY10.83M CNY
Depreciation and amortization27.59M CNY96.26M CNY160.78M CNY73.52M CNY76.23M CNY
Operating income97.6M CNY−89.06M CNY−575.26M CNY−726.34M CNY−1.64B CNY
Net income379.51M CNY81.43M CNY−322.59M CNY−636.06M CNY−1.54B CNY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
90%
9 beats, 1 miss, 0 met estimates
Average EPS surprise
+71.77%
10 comparable reports
Latest EPS result
0.12
Estimate -0.17 · Beat by 165.96%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.30.09-0.13-0.34Q3 '23BeatQ1 '24BeatQ3 '24No estimateQ1 '25BeatQ3 '25BeatQ1 '26BeatQ3 '26BeatQ1 '27Estimate
Q3 2023, reported Aug 24, 2023: actual -0.088, estimate -0.112, surprise +20.69%, Beat. Q1 2024, reported Mar 19, 2024: actual -0.027, estimate -0.078, surprise +65.00%, Beat. Q3 2024, reported Aug 20, 2024: actual 0.019, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 12, 2025: actual 0.023, estimate -0.256, surprise +109.11%, Beat. Q3 2025, reported Aug 19, 2025: actual 0.076, estimate -0.257, surprise +129.62%, Beat. Q1 2026, reported Mar 24, 2026: actual 0.256, estimate -0.296, surprise +186.52%, Beat. Q3 2026, reported Aug 18, 2026: actual 0.115, estimate -0.175, surprise +165.96%, Beat. Q1 2027, reported Mar 16, 2027: actual —, estimate -0.08, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates4.8B3.88B2.97B2.06BQ3 '23MissQ1 '24MissQ3 '24No estimateQ1 '25BeatQ3 '25MissQ1 '26MissQ3 '26MissQ1 '27Estimate
Q3 2023, reported Aug 24, 2023: actual 2.4B HKD, estimate 3.08B HKD, surprise -22.03%, Miss. Q1 2024, reported Mar 19, 2024: actual 2.7B HKD, estimate 3.26B HKD, surprise -17.20%, Miss. Q3 2024, reported Aug 20, 2024: actual 2.25B HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 12, 2025: actual 2.89B HKD, estimate 2.49B HKD, surprise +16.17%, Beat. Q3 2025, reported Aug 19, 2025: actual 2.73B HKD, estimate 4.61B HKD, surprise -40.84%, Miss. Q1 2026, reported Mar 24, 2026: actual 3.31B HKD, estimate 4.19B HKD, surprise -21.06%, Miss. Q3 2026, reported Aug 18, 2026: actual 2.87B HKD, estimate 3.17B HKD, surprise -9.55%, Miss. Q1 2027, reported Mar 16, 2027: actual —, estimate 3.32B HKD, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Dividend

Ex-dividend Dec 6, 2024

HK$9.70

Special

Record Dec 9, 2024 · Payment Jan 24, 2025

1833.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.1

-4.23%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.74

-3.03%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$222.2

-2.54%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.40

-5.10%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.34

-5.26%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.35

-2.98%

Continue in GoAI

Research 1833.HK

research.disclaimer